Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies. Effective July 1, 2025, CVS Caremark will place Novo Nordisk’s Wegovy (semaglutide) injection 2.4 mg on its largest commercial template formularies as the preferred GLP-1 medication for patients with obesity.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head trial of the blockbuster weight-loss medications.

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1, Caremark will prioritize Wegovy on its standard formularies — or lists of covered drugs — making it the preferred GLP-1 drug for obesity.